Trials / Conditions / Myeloid Malignancy

Myeloid Malignancy

24 registered clinical trials studyying Myeloid Malignancy — 15 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Germline Testing for Predisposition to Myeloid Malignancies NCT07112287	Christopher Reilly	N/A
Recruiting	Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories NCT07263074	University of Rochester	N/A
Recruiting	Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant NCT06129734	Benjamin Tomlinson	Phase 1 / Phase 2
Recruiting	Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies NCT07044544	University of Alabama at Birmingham	Phase 1
Recruiting	HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML NCT06594445	Masonic Cancer Center, University of Minnesota	Phase 1
Not Yet Recruiting	Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Pa NCT06090513	Bien-Willner Physicians Group PA	—
Withdrawn	MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies NCT06543511	Dana-Farber Cancer Institute	N/A
Recruiting	Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML NCT06621212	First Affiliated Hospital of Zhejiang University	Phase 2
Recruiting	A Study of GLB-001 in Patients With Myeloid Malignancies NCT06378437	Hangzhou GluBio Pharmaceutical Co., Ltd.	Phase 1
Recruiting	A Telehealth Advance Care Planning Intervention NCT05875805	University of Rochester	N/A
Recruiting	A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies NCT07011186	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1 / Phase 2
Recruiting	Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML NCT06434662	First Affiliated Hospital of Zhejiang University	Phase 2
Terminated	Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Mali NCT05579769	St. Jude Children's Research Hospital	Phase 2
Recruiting	Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. NCT05841771	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 2
Unknown	Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies NCT05583175	Xianmin Song, MD	Phase 2
Active Not Recruiting	Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms NCT05455294	Jacqueline Garcia, MD	Phase 1
Terminated	T-cell Receptor α/β Depleted Donor Lymphocyte Infusion NCT05350163	Guenther Koehne	Phase 1
Recruiting	Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML NCT04501120	Ascentage Pharma Group Inc.	Phase 1 / Phase 2
Unknown	Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations NCT04906031	First Affiliated Hospital of Jinan University	Phase 2
Completed	APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies NCT04214860	Aprea Therapeutics	Phase 1
Recruiting	Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant NCT03850418	Henry Ford Health System	Phase 2
Unknown	Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS NCT03855371	Ruijin Hospital	Phase 1
Recruiting	Pre-myeloid Cancer and Bone Marrow Failure Clinic Study NCT02958462	Mayo Clinic	N/A
Terminated	Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hem NCT01596699	University of California, San Francisco	Phase 2